{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-278334","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.981315+00:00","generated_at":"2026-06-08T01:15:10.033147+00:00","sec_items":["1.01","3.02","5.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Homology Medicines to merge with Q32 Bio, valuing Q32 at $195M; CEO and CFO terminated","bullets":["All-stock merger ascribes Q32 equity value of $195M; Homology equity ~$80M; Q32 stockholders to receive Homology common shares.","Q32 to raise $42M in concurrent financing from accredited investors immediately before close.","Combined board to have 9 members: 2 from Homology, 7 from Q32 (indicating Q32 control).","Q32 holders with 74.1% of Q32 capital stock and Homology holders with 18.2% of common stock support deal via support agreements.","CEO Albert Seymour and CFO W. Bradford Smith terminated; Paul Alloway named President/COO/PEO; Charles Michaud named VP/Controller/Treasurer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-278334","json":"https://secwatch.observer/filing/0001193125-23-278334.json","markdown":"https://secwatch.observer/filing/0001193125-23-278334.md","text":"https://secwatch.observer/filing/0001193125-23-278334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/d350392d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:15:10.033147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f6fb2b3bb","claim":"W. Bradford Smith was terminated as Chief Financial and Business Officer and Treasurer at Q32 Bio Inc..","evidence_excerpt":"the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial and Business Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"628252a9d7","claim":"Albert Seymour resigned as Director at Q32 Bio Inc..","evidence_excerpt":"Dr. Seymour resigned from the Company’s board of directors, effective as of November 17, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d624010f07","claim":"Albert Seymour was terminated as President and Chief Executive Officer at Q32 Bio Inc..","evidence_excerpt":"the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f6676612b5","claim":"Paul G. Alloway was appointed as President, Chief Operating Officer and Secretary at Q32 Bio Inc..","evidence_excerpt":"the Board (i) appointed Paul G. Alloway, Ph.D., who currently serves as the Company’s Chief Legal Officer and Secretary, as the Company’s President, Chief Operating Officer and Secretary, and designated Dr. Alloway as the Company’s principal executive officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Chief Operating Officer and Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}